All articles tagged with #ventyx biosciences
Originally Published 4 days ago — by Eli Lilly
Eli Lilly is acquiring Ventyx Biosciences in a $1.2 billion all-cash deal to enhance its pipeline of oral therapies targeting inflammation-related diseases across various medical fields, aiming to address high unmet medical needs.
Originally Published 5 days ago — by Yahoo Finance
Eli Lilly is in advanced negotiations to acquire Ventyx Biosciences for over $1 billion, which would expand Lilly's portfolio to include treatments for inflammatory bowel diseases and other conditions, with an announcement expected soon.
Originally Published 2 years ago — by Investor's Business Daily
Biotech company Ventyx Biosciences saw its stock plummet by over 80% after its psoriasis drug, VTX958, failed to meet efficacy expectations in Phase 2 testing. Only two out of four doses showed statistically significant improvements in symptoms, leading the company to abandon further development in the highly competitive psoriasis market. Ventyx is terminating the psoriasis study and an ongoing test in psoriatic arthritis but will continue studying VTX958 in patients with Crohn's disease.